Brief: Cipla GCEO Vohra Says Co Will Take Eli Lilly's Yurpeak (Mounjaro) Into Tier 2, Tier 3 Markets With Partnership
Oct 30 (Reuters) - CIPLA GCEO VOHRA - ACHIN GUPTA WILL BE GCEO DESIGNATE FROM JAN 1 CIPLA GCEO VOHRA - WE WILL TAKE LILLY'S YURPEAK (MOUNJARO) INTO TIER 2 AND TIER 3 MARKETS WITH PARTNERSHIP CIPLA GCEO VOHRA - THERE IS ENOUGH CAPACITY FROM ELI LILLY ON MOUNJARO Source text: [ID:] Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate